[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thromboprophylaxis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thromboprophylaxis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100531111","phase-3-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-lower-limb-trauma-requiring-brace-or-casting-100531111",false,"NCT06195540","RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST","Inclusion Criteria:\n\n* Patient aged 18 or over ;\n* Consultation in an emergency department of a participating centre;\n* Trauma to the lower limb requiring rigid or semi-rigid orthopaedic immobilisation;\n* Expected duration of orthopaedic immobilisation of at least 2 weeks;\n* TRiP(cast) score ≥ 7 ;\n* Patient affiliated to or benefiting from a social security scheme;\n* Patient with prior informed consent.\n\nExclusion Criteria:\n\n* Patient that have to be hospitalized after emergency department for other reason than lower limb trauma\n* Active bleeding or high risk of bleeding,\n* Known contraindication to rivaroxaban or LMWH;\n* Taking any anticoagulant or antiplatelet agent before the trauma (only antithrombotic authorised: aspirin \\\u003C 325mg\u002Fd);\n* Pregnant or breastfeeding woman;\n* Any factor making 3-month follow-up impossible; 6. Patient subject to a legal protection measure, Imprisonment 7. Participation in any interventional study which modifies patient care or could influence study evaluation criteria","ALL","18 Years",{"count":20,"type":21},1424,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score \\\u003C7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms.\n\nThe aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.",[27,28,29,30,31,32],"Venous Thromboembolism","Deep Vein Thrombosis","Pulmonary Embolism","Lower Limb Trauma","Thromboprophylaxis","Immobilisation",[34,35,36,37,38,39],"Emergency department","direct oral anticoagulant","rivaroxaban","Low-Molecular-weight heparin","randomized control trial","Prevent VTE","RECRUITING","2026-06-22",{"date":43,"type":44},"2026-06-25","ACTUAL",{"date":46,"type":44},"2024-07-19",{"date":48,"type":21},"2028-11-19",{"name":50,"class":51},"University Hospital, Angers","OTHER_GOV",37,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100622513","pharmacokinetic-profiles-of-subcutaneous-enoxaparin-for-thromboprophylaxis-in-critically-ill-patients-with-renal-failure-treated-or-not-with-continuous-veno-veinous-hemofiltration-100622513","NCT07384598","Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","AKI-ENOXA","Inclusion Criteria:\n\n* Age \\> 18 year old\n* Hospitalized in the ICU.\n* Equiped with an arterial line.\n* Indication for thromboprophylaxis with a daily prophylactic dose of enoxaparin.\n* Additionnally:\n\n  * For cohort 1: severe renal failure (KDIGO stage ≥2) without CVVH AND SOFA score ≥4.\n  * For cohort 2: severe renal failure (KDIGO stage ≥2) with CVVH AND sequential organ failure assessment (SOFA) score ≥4.\n  * For cohort 3: no renal failure (creatinine clearance \\> 60 ml\u002Fmin)\n\nExclusion Criteria:\n\n* Platelet count \\\u003C 50 000\u002Fμl.\n* CHILD PUGH stage C cirrhosis.\n* Known coagulation disorder.\n* Patient treated in the last 3 days with direct oral anticoagulants.\n* Patient treated in the last 24h with LMWH before enrollment.\n* High bleeding risk with contra indication for standard dose of LMWH prophylaxis, as per investigator judgment\n* Indication for therapeutic anticoagulation (including CVVH with systemic heparin anticoagulation).\n* Body weight \\\u003C 50 kg or \\> 120 kg.\n* Evidence of recovery of renal function before enrollment, based on investigator judgement.",{"count":61,"type":21},60,[63],"NA","Thromboprophylaxis is recommended for critically ill patients without contraindications and is usually achieved by the subcutaneous daily administration of a low dose of low molecular weight heparin (LMWH). The efficacy of this measure can be assessed by measuring the anticoagulation level obtained in the blood by dosing the anti-Xa activity. However, multiple studies have shown that anti-Xa activities in critically ill patients in the intensive care unit (ICU) are much lower, and below the desired range, than their ward counterparts.\n\nLMWH elimination depends on kidney function and reduced dosing is recommended for patients with renal failure, treated or not with renal replacement therapy (continuous veno-venous hemofiltration (CVVH)). However, some scarce data suggest that even critically ill patients with renal failure treated with reduced or even with standard doses of LMWH, also have lower anti-Xa activities (below the desired range). If confirmed, this finding may suggest that reduced or even standard dosing of LMWH for thromboprophylaxis in critically ill patients with renal failure should be replaced by another dosing regimen or another route of administration. Therefore, this study aims to better characterize the pharmacokinetic profiles of LMWH after administration of a prophylactic dose of enoxaparin daily in patients with renal failure treated or not with CVVH, and to compare them to patients with no renal failure.",[31,66,67],"Critical Illness","Intensive Care (ICU)",[69],"thromboprophylaxis","NOT_YET_RECRUITING","2026-01-29",{"date":73,"type":44},"2026-02-03",{"date":75,"type":21},"2026-02-01",{"date":77,"type":21},"2027-12-31",{"name":79,"class":80},"Clinique Saint Pierre Ottignies","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100605297","phase-3-apixaban-to-prevent-venous-thromboembolism-in-ambulatory-lung-cancer-patients-undergoing-systemic-anticancer-treatment-100605297","NCT07160686","Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","A Phase III, Multicentre, Double Blind, Placebo-Controlled, Randomised Clinical Trial of Apixaban THROMBOprophylaxiS TO Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","THROMBO-STOP","Inclusion criteria\n\n* Age ≥ 16 years\n* Newly diagnosed locally advanced or metastatic primary lung cancer (histologically\u002F cytologically confirmed) or disease progression after complete or partial remission commencing a new course of SACT alone or as CRT\n* Ambulatory (receiving outpatient SACT)\n\nExclusion criteria\n\n* Hypersensitivity to apixaban or to any of the listed SmPC excipients\n* Active clinically significant bleeding\n* Lesion or condition considered a significant risk factor for major bleeding\n* Hepatic disease associated with impaired synthetic function\n* Platelet count \\\u003C 50 x 109 \u002FL\n* Elevated liver enzymes ALT\u002FAST \\> 2 x ULN or total bilirubin ≥ 1.5 x ULN\n* Renal failure (creatinine clearance \\\u003C 15ml\u002Fmin)\n* Weight \\\u003C 40kg\n* Estimated life expectancy \\\u003C 6 months\n* Continuous anticoagulation (e.g., unfractionated heparin, low molecular weight heparins, heparin derivatives and oral anticoagulants) for other medical conditions\n* The usage of medications contraindicated with apixaban\n* Pregnancy\n* Breast feeding\n* Judgement by the Investigator that the participant is unsuitable to participate in the trial and the participant is unlikely to comply with trial procedures, restrictions and requirements\n* Inability to consent\n* Receiving SACT for potentially resectable \u002F resectable lung cancer as part of neo-adjuvant or adjuvant treatment\n* SACT with significant potential DDI with apixaban (section 7.2.3)","16 Years",{"count":91,"type":21},1456,[24],"The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant (\"blood thinner\") that makes the blood less sticky to prevent blood clots forming.\n\nThe trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer.\n\nParticipants will receive the following treatment:\n\n• Apixaban or placebo, 2.5mg taken by mouth twice a day for 6 months. This treatment will be taken in addition to any treatment that they are receiving to treat their lung cancer.\n\nParticipants will need to:\n\n* Sign a consent form to enter the trial.\n* Take the trial treatment as directed by the research team\n* Complete a participant diary to record when they took the trial treatment\n* Complete the Quality of Life and Health resource use questionnaires.\n* Female participants of childbearing potential must use adequate contraception during the trial and for at least 2 days after trial treatment has finished.",[31],"2025-09-01",{"date":97,"type":44},"2025-09-08",{"date":99,"type":21},"2026-03-02",{"date":101,"type":21},"2030-03-30",{"name":103,"class":80},"University of Birmingham",1]